These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35536535)

  • 1. Primary aldosteronism in pregnancy.
    Forestiero V; Sconfienza E; Mulatero P; Monticone S
    Rev Endocr Metab Disord; 2023 Feb; 24(1):39-48. PubMed ID: 35536535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of primary aldosteronism.
    Vilela LAP; Almeida MQ
    Arch Endocrinol Metab; 2017; 61(3):305-312. PubMed ID: 28699986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
    Weiner ID
    Semin Nephrol; 2013 May; 33(3):265-76. PubMed ID: 23953804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.
    Carey RM
    Curr Cardiol Rep; 2016 Oct; 18(10):97. PubMed ID: 27566330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.
    Amar L; Baguet JP; Bardet S; Chaffanjon P; Chamontin B; Douillard C; Durieux P; Girerd X; Gosse P; Hernigou A; Herpin D; Houillier P; Jeunemaitre X; Joffre F; Kraimps JL; Lefebvre H; Ménégaux F; Mounier-Véhier C; Nussberger J; Pagny JY; Pechère A; Plouin PF; Reznik Y; Steichen O; Tabarin A; Zennaro MC; Zinzindohoue F; Chabre O
    Ann Endocrinol (Paris); 2016 Jul; 77(3):179-86. PubMed ID: 27315757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.
    Stowasser M; Gordon RD; Gunasekera TG; Cowley DC; Ward G; Archibald C; Smithers BM
    J Hypertens; 2003 Nov; 21(11):2149-57. PubMed ID: 14597859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary aldosteronism and pregnancy.
    Landau E; Amar L
    Ann Endocrinol (Paris); 2016 Jun; 77(2):148-60. PubMed ID: 27156905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
    Pechère-Bertschi A; Herpin D; Lefebvre H
    Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary aldosteronism: Practical recommendations for treatment and follow-up.
    Araujo-Castro M; Pascual-Corrales E; Martín Rojas P; Parra Ramírez P
    Hipertens Riesgo Vasc; 2023; 40(4):215-221. PubMed ID: 37993292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Aldosteronism.
    Quencer KB; Rugge JB; Senashova O
    Am Fam Physician; 2023 Sep; 108(3):273-277. PubMed ID: 37725461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Aldosteronism: Present and Future.
    Funder JW
    Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
    Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection.
    Chan CK; Chang YY; Tsai YC; Chen ZW; Wu CY; Huang WC; Yen IW; Wu KH; Wu VC; Lin YH;
    J Formos Med Assoc; 2021 Oct; 120(10):1811-1820. PubMed ID: 33906783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of primary hyperaldosteronism.
    Araujo-Castro M
    Med Clin (Barc); 2020 Oct; 155(7):302-308. PubMed ID: 32586668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of drug-based and surgical treatments for primary aldosteronism.
    Steichen O; Lorthioir A; Zinzindohoue F; Plouin PF; Amar L
    Adv Chronic Kidney Dis; 2015 May; 22(3):196-203. PubMed ID: 25908468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients.
    Hyla-Klekot L; Kokot F
    Pol Arch Med Wewn; 2013; 123(10):547-51. PubMed ID: 24104388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.